BRPI0412512A - método de tratamento ou prevenção de distúrbios do sistema nervoso central com compostos tendo seletividade para a subunidade alfa 3 do receptor de benzodiazepina - Google Patents
método de tratamento ou prevenção de distúrbios do sistema nervoso central com compostos tendo seletividade para a subunidade alfa 3 do receptor de benzodiazepinaInfo
- Publication number
- BRPI0412512A BRPI0412512A BRPI0412512-6A BRPI0412512A BRPI0412512A BR PI0412512 A BRPI0412512 A BR PI0412512A BR PI0412512 A BRPI0412512 A BR PI0412512A BR PI0412512 A BRPI0412512 A BR PI0412512A
- Authority
- BR
- Brazil
- Prior art keywords
- nervous system
- central nervous
- selectivity
- compounds
- system disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"MéTODO DE TRATAMENTO OU PREVENçãO DE DISTúRBIOS DO SISTEMA NERVOSO CENTRAL COM COMPOSTOS TENDO SELETIVIDADE PARA A SUBUNIDADE ALFA 3 DO RECEPTOR DE BENZODIAZEPINA". A presente invenção refere-se ao uso de 1-ar (alq) ilimidazolin-2onas que contêm um radical amina dissubstituído na posição 4 para o tratamento ou prevenção de distúrbios do sistema nervoso central incluindo depressão, ansiedade, distúrbios do movimento, e especialmente distonia, e distúrbios psicóticos, e especialmente esquizofrenia e sintomas psicóticos associados com outros distúrbios mentais.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48667803P | 2003-07-11 | 2003-07-11 | |
PCT/EP2004/006989 WO2005004867A2 (en) | 2003-07-11 | 2004-06-28 | Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0412512A true BRPI0412512A (pt) | 2006-09-19 |
Family
ID=34062138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0412512-6A BRPI0412512A (pt) | 2003-07-11 | 2004-06-28 | método de tratamento ou prevenção de distúrbios do sistema nervoso central com compostos tendo seletividade para a subunidade alfa 3 do receptor de benzodiazepina |
Country Status (17)
Country | Link |
---|---|
US (2) | US20050032863A1 (pt) |
EP (2) | EP1646386A2 (pt) |
JP (1) | JP2009513539A (pt) |
KR (1) | KR20060032633A (pt) |
CN (2) | CN101254189A (pt) |
AR (1) | AR045013A1 (pt) |
AU (1) | AU2004255414A1 (pt) |
BR (1) | BRPI0412512A (pt) |
CA (1) | CA2531861A1 (pt) |
MX (1) | MXPA05013196A (pt) |
NO (1) | NO20060686L (pt) |
NZ (1) | NZ544251A (pt) |
RU (1) | RU2354377C2 (pt) |
TW (1) | TW200512197A (pt) |
UA (1) | UA87982C2 (pt) |
WO (1) | WO2005004867A2 (pt) |
ZA (1) | ZA200509169B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007101802A1 (en) * | 2006-03-08 | 2007-09-13 | F. Hoffmann-La Roche Ag | 4-amino-1,5-substituted 1,5-dihydro-imidazol-2-ones |
AU2010289281A1 (en) | 2009-09-04 | 2012-04-12 | Vanderbilt University | mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
RU2014109074A (ru) | 2011-08-12 | 2015-09-20 | Бёрингер Ингельхайм Ветмедика Гмбх | ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ |
CN104199105A (zh) * | 2014-08-27 | 2014-12-10 | 中国石油天然气集团公司 | 高密度三维勘探中初至的拾取方法及拾取装置 |
CN109564229A (zh) * | 2016-07-11 | 2019-04-02 | 兰维尔健康有限公司 | 基于味觉识别的诊断相关性的方法 |
CA3146837A1 (en) * | 2019-08-06 | 2021-02-11 | Ulf Simonsen | Compound for combination treatment |
KR102489109B1 (ko) * | 2020-06-02 | 2023-01-16 | 부산대학교 산학협력단 | 아세틸콜린 수용체 변이 유전자를 유효성분으로 포함하는 근긴장 이상증 치료용 조성물 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI90869C (fi) * | 1986-11-14 | 1994-04-11 | Tanabe Seiyaku Co | Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi |
WO1997000931A1 (en) | 1995-06-23 | 1997-01-09 | Bausch & Lomb Incorporated | Method for cleaning contact lenses utilizing polysulfonates |
DE19532668A1 (de) * | 1995-09-05 | 1997-03-06 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung |
US5869481A (en) | 1995-09-05 | 1999-02-09 | Arzneitmittelwerk Dresden G.M.B.H. | Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making |
US5861423A (en) * | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
DE19721580A1 (de) * | 1997-05-23 | 1998-11-26 | Dresden Arzneimittel | Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen |
WO1999037370A1 (en) | 1998-01-22 | 1999-07-29 | Precedence Publishing, Inc. | Game using collectibles as playing pieces |
GB9821179D0 (en) | 1998-09-30 | 1998-11-25 | Merck Sharp & Dohme | Therapeutic use |
GB9929687D0 (en) | 1999-12-15 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
GB0122696D0 (en) * | 2001-09-20 | 2001-11-14 | Merck Sharp & Dohme | Therapeutic agents |
US20050070537A1 (en) * | 2002-10-10 | 2005-03-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
-
2004
- 2004-06-28 MX MXPA05013196A patent/MXPA05013196A/es unknown
- 2004-06-28 CN CNA200710169458XA patent/CN101254189A/zh active Pending
- 2004-06-28 EP EP04740387A patent/EP1646386A2/en not_active Withdrawn
- 2004-06-28 NZ NZ544251A patent/NZ544251A/en unknown
- 2004-06-28 CA CA002531861A patent/CA2531861A1/en not_active Abandoned
- 2004-06-28 RU RU2006104118/14A patent/RU2354377C2/ru not_active IP Right Cessation
- 2004-06-28 AU AU2004255414A patent/AU2004255414A1/en not_active Abandoned
- 2004-06-28 US US10/878,987 patent/US20050032863A1/en not_active Abandoned
- 2004-06-28 EP EP08168609A patent/EP2027856A1/en not_active Withdrawn
- 2004-06-28 BR BRPI0412512-6A patent/BRPI0412512A/pt not_active IP Right Cessation
- 2004-06-28 CN CNA2004800199698A patent/CN1822836A/zh active Pending
- 2004-06-28 JP JP2006519793A patent/JP2009513539A/ja not_active Withdrawn
- 2004-06-28 KR KR1020067000739A patent/KR20060032633A/ko not_active Application Discontinuation
- 2004-06-28 WO PCT/EP2004/006989 patent/WO2005004867A2/en active Application Filing
- 2004-06-28 UA UAA200600251A patent/UA87982C2/ru unknown
- 2004-06-29 TW TW093119215A patent/TW200512197A/zh unknown
- 2004-07-02 AR ARP040102355A patent/AR045013A1/es unknown
-
2005
- 2005-11-14 ZA ZA200509169A patent/ZA200509169B/xx unknown
-
2006
- 2006-02-13 NO NO20060686A patent/NO20060686L/no not_active Application Discontinuation
-
2007
- 2007-10-29 US US11/978,362 patent/US20080114032A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2531861A1 (en) | 2005-01-20 |
NZ544251A (en) | 2009-12-24 |
RU2006104118A (ru) | 2006-06-10 |
AU2004255414A1 (en) | 2005-01-20 |
JP2009513539A (ja) | 2009-04-02 |
TW200512197A (en) | 2005-04-01 |
CN1822836A (zh) | 2006-08-23 |
US20050032863A1 (en) | 2005-02-10 |
NO20060686L (no) | 2006-03-14 |
AR045013A1 (es) | 2005-10-12 |
KR20060032633A (ko) | 2006-04-17 |
MXPA05013196A (es) | 2006-03-09 |
CN101254189A (zh) | 2008-09-03 |
US20080114032A1 (en) | 2008-05-15 |
RU2354377C2 (ru) | 2009-05-10 |
WO2005004867A2 (en) | 2005-01-20 |
EP1646386A2 (en) | 2006-04-19 |
EP2027856A1 (en) | 2009-02-25 |
ZA200509169B (en) | 2006-07-26 |
UA87982C2 (ru) | 2009-09-10 |
WO2005004867A3 (en) | 2005-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0209558A (pt) | Novos compostos de arilsulfonamida para o tratamento de obesidade, diabetes tipo ii e distúrbios do snc | |
BRPI0518581A2 (pt) | compostos de cromanilurÉia que inibem o receptor do subtipo 1 do recepetor vanilàide (vr1) e usos destes | |
BR0314393A (pt) | Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia | |
GT200200143A (es) | Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales o neuronales | |
BR0114552A (pt) | N1- (benzenosulfonil) indóis 2-,3-,4-, 5- substituìdos e seu uso em terapia | |
BRPI0413860A (pt) | [1,8]naftiridin-2-onas e compostos relacionados para o tratamento de esquizofrenia | |
CY1111206T1 (el) | Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων | |
AR032086A1 (es) | Combinaciones de farmacos | |
CL2007001555A1 (es) | Compuestos derivados de 4-amino-pirido[3,2-e]pirazinas; inhibidores de fosfodiesterasa 10 (pde10); procedimeinto de preparacion; composicion framaceutica; combinacion farmaceutica, y sus uso en el tratamiento de trastornos neurologicos y psiquiatricos, tales como esquizofrenia y otros trastornos psicoticos. | |
BRPI0516463A (pt) | cánula escalonada e conjunto de cánula | |
BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
BR0209812A (pt) | Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas | |
BR0111892A (pt) | Bis-arilsulfonas | |
BRPI0508084A (pt) | método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo | |
CL2003002050A1 (es) | Compuestos derivados de 1-piperazin-1,2-dihidroindeno, su composicion farmaceutica y el uso de esta para tratar enfermedades del sistema nervioso central. | |
DE60234118D1 (de) | Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen | |
BRPI0415769A (pt) | alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as | |
BR0309486A (pt) | Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas | |
ECSP045156A (es) | Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6 | |
BRPI0412512A (pt) | método de tratamento ou prevenção de distúrbios do sistema nervoso central com compostos tendo seletividade para a subunidade alfa 3 do receptor de benzodiazepina | |
BR0113590A (pt) | 7-oxo-piridopirimidinas | |
DE60227576D1 (de) | 3,6-DISUBSTITUIERTE AZABICYCLO i3.1.0 -HEXANDERIVATIVE ALS ANTAGONISTEN DES MUSCARINREZEPTORS | |
BR0010151A (pt) | Inibidores do sistema de clivagem de glicina como antipsicóticos potenciais | |
BRPI0414622A (pt) | métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias | |
BR0112130A (pt) | Composições farmacêuticas e métodos para uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: ELBION GMBH (DE) Free format text: ALTERADO DE: ELBION AG |
|
B25A | Requested transfer of rights approved |
Owner name: BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) Free format text: TRANSFERIDO DE: ELBION GMBH |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |